Abstract:Background: There is overwhelming evidence that blood pressure (BP)-lowering treatment can reduce cardiovascular outcomes also in the elderly, but some important aspects influencing medical practice are controversial as sufficient evidence has not been provided by single randomized controlled trials (RCTs), whereas evidence may result from a systematic search and meta-analysis of all available data. Objectives: The following clinically relevant issues concerning the effects of BP lowering in older and younger individuals have been investigated: differences in benefits; the oldest and the youngest age range for which evidence of BP-lowering effects is available; the SBP level at which BP-lowering treatment should be initiated; the SBP and DBP levels treatment should be aimed at; differences in treatment burdens and harms. Methods: A database we previously identified of 72 BP-lowering RCTs in 260 210 patients was searched for separately reported data on older and younger individuals [cutoffs of 65 (primary analyses), 70, 75, 80, 60 and 55 years). The data were further stratified according to the levels of baseline (untreated) BP, and of on-treatment achieved SBP or DBP. Seven fatal and nonfatal outcomes were considered for benefits. Burdens and harms were investigated as permanent treatment discontinuations for adverse events, and hypotension/syncope. Risk ratios and absolute risk changes were calculated by a random effects model. Effects at older and younger ages were compared by heterogeneity test. Results: Thirty-two RCTs provided data on 96 549 patients older than 65 years, and 31 RCTs on 114 009 patients younger than 65 years. All cardiovascular outcomes were significantly reduced by treatment both in older and younger individuals, without significant age-dependent differences in relative risk reduction but with significantly higher absolute risk reductions in older individuals. The extreme age ranges for which evidence of significant benefits of treatment were available was greater than 80 and less than 55 years. Only one RCT provided data on benefits of BP-lowering at age greater than 65 when treatment was initiated at SBP values in the grade 1 range, but more consistent evidence was provided when age was greater than 60 years. Both in patients older and younger than 65 years, significant reductions of cardiovascular outcomes were found at on-treatment SBP less than 140 mmHg and DBP less than 80 mmHg. There was no evidence that treatment discontinuations for adverse events or hypotension/syncope were more frequent at age greater than 65. Conclusion: Antihypertensive treatment should be recommended to all individuals with elevated BP, independent of age. The prudent recommendation to initiate treatment at SBP values 140–159 mmHg is supported at older age defined as greater than 60 years. SBP and DBP values lower than 140 mmHg and, respectively, 80 mmHg can be aimed at with incremental benefits without disproportionate burdens until age 80 years, above which available evidence is for benefits at on-treatment SBP 140–149 mmHg.

Effects of physical activity on blood pressure and mortality among aged hypertensive patients: A cross-sectional study

Effect Of Total, Domain-Specific, And Intensity-Specific Physical Activity On All-Cause And Cardiovascular Mortality Among Hypertensive Adults In China

Physical activity lower blood pressure and mortality in hypertensive patients with diabetes: data from National Health and Nutrition Examination Survey (NHANES) 1999-2018

Hypertension in China: the Gap Between Policy and Practice

The Effects of Blood Pressure Reduction in Older Patients: An Overview of Five Randomized Controlled Trials in Elderly Hypertensives

A network meta-analysis comparative the efficacy of angiotensin-converting enzyme inhibitors and calcium channel blockers in hypertension

Effects Of Intensive Antihypertensive Treatment On Chinese Hypertensive Patients Older Than 70years

The effect of hypertensive diseases on death patterns and healthy ageing in Pudong, Shanghai: a population-based study

Longitudinal Change in Blood Pressure is Associated with Cardiovascular Disease Mortality in a Chinese Cohort.

Dose–response association between physical activity and blood pressure among Chinese adults: a nationwide cross-sectional study

The relationship between hypertension and physical activity in middle-aged and older adults controlling for demographic, chronic disease, and mental health variables

Excessive Physical Activity Duration May Be a Risk Factor for Hypertension in Young and Middle-Aged Populations.

Relationship Of Blood Pressure With Mortality And Cardiovascular Events Among Hypertensive Patients Aged >= 60 Years In Rural Areas Of China A Strobe-Compliant Study

Association between physical activity and hypertension: A retrospective study

The Association Between Daily Physical Activity and Risk of Hypertension in Middle-Aged and Older Adults: A Nationwide Cohort Study in China

Effects of aerobic exercise in controlling blood pressure

The effect of physical activity intervention on blood pressure in 18 low and middle-income countries: a systematic review and meta-analysis of randomized controlled trials

The association between daily total physical activity and risk of cardiovascular disease among hypertensive patients: a 10-year prospective cohort study in China

STEP to blood pressure management of elderly hypertension: evidence from Asia

Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 – benefits and adverse events in older and younger patients with hypertension overview, meta-analyses and meta-regression analyses of randomized trials

Hypertension and cellular senescence